Application of combination of Vandetanib and pharmaceutically acceptable salt thereof and nifedipine and pharmaceutically acceptable salt thereof in preparation of medicines for treating cancer and long Q-T interphase syndrome

By combining vandetanib with nifedipine, a combination of drugs used to treat cancer and long Q-T interval syndrome is solved, the problem of cardiotoxicity of vandetanib is reduced, and the risk of QT interval prolongation is maintained or increased. Treatment effect, avoid the decrease in effect caused by the decrease in drug use.

CN118892485AInactive Publication Date: 2024-11-05SCOPE TECHNOLOGY LTD BEIJING
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410865800.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-28
Publication Date
2024-11-05
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Vandertanib is cardiotoxic in the treatment of cancer, especially the risk of prolonging the QT interval and malignant arrhythmias, and the reduction in its use can affect the therapeutic effect.

Method used

Vandtanib is prepared in combination with nifedipine and its pharmaceutically acceptable salts to form a pharmaceutical composition for the treatment of cancer and long Q-T interval syndrome, and different dosage forms are prepared by adjusting the drug molar ratio and adding excipients. Including tablets, effervescent tablets, granules, etc., to ensure that the efficacy of the medicine is not affected.

Benefits of technology

Reduces the cardiotoxicity of vandetani, maintains or improves its efficacy against cancer, reduces the risk of malignant arrhythmias caused by QT interval prolongation, and does not affect the IC50 value of vandetani, improves patients' use due to cardiotoxicity. The issue of quantity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118892485A_ABST
    Figure CN118892485A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medicines, and provides application of Vandetanib and pharmaceutically acceptable salts thereof and nifedipine and pharmaceutically acceptable salts thereof in preparation of medicines for treating cancers and long Q-T interphase syndromes, and the two medicines are combined for use, so that the cardiotoxicity of the Vandetanib can be reduced, the cancer curative effect of the Vandetanib can be improved, and the curative effect of the Vandetanib is improved. On one hand, the combination of the Vandetanib and the Vandetanib does not influence the IC50 value of the Vandetanib for treating cancers, which shows that the combination has small influence on the efficacy of the Vandetanib and can improve the efficacy so as to reduce the dosage of the Vandetanib, and on the other hand, the combination of the Vandetanib and the Vandetanib can reduce the cardiotoxicity of the Vandetanib and treat the long Q-T interphase syndrome. The occurrence risk of malignant arrhythmia caused by QT interval prolonging is reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to the use of vandetanib and its pharmaceutically acceptable salts in combination with nifedipine and its pharmaceutically acceptable salts in the preparation of drugs for treating cancer and long QT syndrome. Background Art

[0002] Long QT syndrome (LQTS), also known as delayed repolarization syndrome, refers to the prolonged QT interval on the electrocardiogram, accompanied by abnormal T wave and (or) u wave morphology. It is usually diagnosed based on QTc ≥ 470ms for men and QTc ≥ 480ms for women. Clinically, it manifests as ventricular arrhythmias, and even serious complications such as syncope and sudden death due to repeated occurrence of torsades de pointes. Most patients' symptoms occur during exercise, emotional tension, and excitement. Syncope generally lasts 1-2 minutes, and some patients die suddenly during sleep.

[0003] LQTS is divided into two categories: congenital hereditary and acquired, depending on the presence or absence of secondary factors. Congenital long QT syndrome includes autosomal dominant Romano Ward syndrome and autosomal recessive Jervell Lange-Nielsen syndrome. The former has normal hearing, while the latter is accompanied by congenital deafness. Many scholars have proposed different hypotheses about the causes of congenital long QT syndrome, including imbalance of sympathetic innervation, abnormal myocardial repolarization, cardiac nerve degeneration, and congenital myocardial enzyme deficiency. It is believed that congenital long QT syndrome is caused by mutations in genes that regulate ion channels of ventricular myocyte membrane repolarization. Common causes of acquired long QT syndrome include electrolyte metabolism disorders, bradyarrhythmias, central nervous system diseases, coronary heart disease, drug effects, and other disease factors. At the same time, this is also a key factor for many drugs to cause arrhythmias. Many drugs were not allowed to be marketed or marked with black window warnings before they were launched because of the risk of LQTS, restricting the use of people.

[0004] LQTS is caused by excessive prolongation of the action potential repolarization duration. The action potential repolarization is precisely regulated by a series of ion channels, including inward currents such as INa and ICa and outward currents such as IK. The excessive prolongation of the action potential repolarization is caused by the imbalance of internal and external currents, which leads to LQTS. Therefore, ion channel inhibitors can be used to restore the balance of internal and external currents, thereby shortening the excessively prolonged QT interval and reducing the risk of malignant arrhythmias such as torsades de pointes. Calcium channel blockers, also called calcium antagonists, mainly inhibit the influx of calcium ions in the second phase of myocardial depolarization (one of the main inward currents of the action potential), which can shorten the action potential duration, thereby shortening the patient's QT interval and reducing the risk of malignant arrhythmias.

[0005] Vandetanib is an orally active small molecule multi-target tyrosine kinase inhibitor developed by AstraZeneca plc in the UK. It is mainly used to treat non-small cell lung cancer (NSCLC) and inoperable, disease-progressive or symptomatic advanced medullary thyroid carcinoma (MTC). Although vandetanib has shown good therapeutic effects, it has many common adverse reactions in clinical practice, the most serious of which is cardiac toxicity. Vandetanib can cause QTc interval prolongation and hypertension, and there have been reports of torsade de pointes (TdP) and sudden death in clinical practice. The molecular formula of vandetanib is C 22 H 24 BrFN4O2, CAS: 443913-73-3, its structural formula is as follows:

[0006]

[0007] Nifedipine, a dihydropyridine calcium channel blocker, is a peripheral and coronary vasodilator used to lower blood pressure and relieve symptoms of angina pectoris and variant angina pectoris. The molecular formula is C 17 H 18 N2O6, CAS: 21829-25-4, its structural formula is as follows:

[0008] Summary of the invention

[0009] Therefore, the technical problem to be solved by the present invention is to provide a use of vandetanib and a pharmaceutically acceptable salt thereof in combination with nifedipine and a pharmaceutically acceptable salt thereof in the preparation of a drug for treating cancer and long QT syndrome. The combined use of the above two drugs, on the one hand, does not affect the IC50 value of vandetanib itself for treating cancer, indicating that the combined use has little effect on the efficacy of vandetanib itself and can reduce the dosage of vandetanib. On the other hand, it can reduce the cardiotoxicity of vandetanib, treat long QT syndrome, and reduce the risk of malignant arrhythmias caused by prolonged QT interval.

[0010] To this end, the present invention provides the following technical solutions:

[0011] Use of vandetanib and its pharmaceutically acceptable salts in combination with nifedipine and its pharmaceutically acceptable salts in preparing drugs for treating cancer and long QT syndrome.

[0012] A pharmaceutical composition comprising the following two active ingredients:

[0013] Vandetanib and pharmaceutically acceptable salts thereof; and

[0014] Nifedipine and pharmaceutically acceptable salts thereof.

[0015] Optionally, the molar ratio of nifedipine and its pharmaceutically acceptable salts to vandetanib and its pharmaceutically acceptable salts is (0.1-0.5):(0.4-3.4).

[0016] Optionally, it also contains pharmaceutically acceptable excipients, which include at least one of excipients, binders, disintegrants, emulsifiers, preservatives, suspending agents, fragrances, pH adjusters, flocculants and deflocculating agents, surfactants, fillers, lubricants, thickeners, humectants, plasticizers, antibacterial agents, coating materials, foaming agents, defoaming agents, bactericidal agents, isotonic regulators, and stabilizers.

[0017] Optionally, the pharmaceutical composition is prepared as a pharmaceutical preparation.

[0018] Optionally, the dosage form of the pharmaceutical preparation is selected from tablets, effervescent tablets, nebulizers, gels, granules, pills, capsules, pellets, suspensions, sustained-release agents, controlled-release agents or injections.

[0019] Optionally, the pharmaceutical preparation is an oral preparation.

[0020] The pharmaceutical composition is used in preparing medicines for treating cancer and long QT syndrome.

[0021] Optionally, the cancer includes thyroid cancer, liver cancer, lung cancer or breast cancer.

[0022] The technical solution of the present invention has the following advantages:

[0023] 1. The present invention provides a method for preparing a drug for treating cancer and long QT syndrome by combining vandetanib and its pharmaceutically acceptable salts with nifedipine and its pharmaceutically acceptable salts. The combination of the two drugs can reduce the cardiotoxicity of vandetanib and increase the cancer efficacy of vandetanib. On the one hand, the combination of the two drugs does not affect the IC50 value of vandetanib itself for treating cancer, indicating that the combination has little effect on the efficacy of vandetanib itself, and can improve the current situation of "patients have to reduce the amount of vandetanib used due to cardiotoxicity, resulting in the drug not reaching the optimal concentration", thereby indirectly increasing the effect of the drug. On the other hand, it can reduce the cardiotoxicity of vandetanib, treat long QT syndrome, and reduce the risk of malignant arrhythmias caused by prolonged QT interval. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0025] Figure 1 Figure 5 is the inhibitory effect of vandetanib on the main ion channels of cardiac action potential repolarization; A is the effect of vandetanib on Nav1.5, i is a representative graph of the effect of different concentrations of vandetanib (laboratory internal number SG7018, the same below) on Nav1.5, and ii is a dose-effect graph of different concentrations of vandetanib on Nav1.5; B is the effect of vandetanib on Kv4.3, i is a representative graph of the effect of different concentrations of vandetanib on Kv4.3, and ii is a dose-effect graph of different concentrations of vandetanib on Kv4.3; C is the effect of vandetanib on hERG, i is a representative graph of the effect of different concentrations of vandetanib on hERG, and ii is a dose-effect graph of different concentrations of vandetanib on hERG; D is the effect of vandetanib on Kir2.1, i is a representative graph of the effect of different concentrations of vandetanib on Kir2.1, and ii is a dose-effect graph of different concentrations of vandetanib on Kir2.1;

[0026] Figure 2 is the IC50 value of vandetanib on the main ion channel of cardiac action potential repolarization;

[0027] Figure 3 Schematic diagram of ECG electrodes, stimulation electrodes and matrix multi-channel electrophysiological mapping system electrode attachment;

[0028] Figure 4The effect of vandetanib on APD of isolated guinea pig hearts. A is a schematic diagram of the mapping position of the heart under high-resolution fluorescence mapping, B is the effect of different concentrations of vandetanib on APD, C is a statistical diagram of the dose-effect of vandetanib on APD, and D is a statistical diagram of the dose-effect of vandetanib on APD30 / APD80;

[0029] Figure 5 The effect of nifedipine on the QT interval of isolated guinea pig hearts. A is a representative graph of ECG under the action of different concentrations of nifedipine, and B is a dose-effect statistical graph of the effect of nifedipine on the QT interval;

[0030] Figure 6 The effects of 300 nM nifedipine combined with vandetanib on the QT interval of isolated guinea pig hearts; A is a representative graph of the effects of different concentrations of vandetanib on the QT interval and a representative graph of the effects of 300 nM nifedipine combined with different concentrations of vandetanib on the QT interval, and B is a quantitative statistical graph of the effects of 300 nM nifedipine combined with different concentrations of vandetanib on the QT interval;

[0031] Figure 7 The effects of 100 nM nifedipine combined with vandetanib on the QT interval of isolated guinea pig hearts; A is a representative graph of the effects of 100 nM nifedipine combined with different concentrations of vandetanib on the QT interval, and B is a quantitative statistical graph of the effects of 100 nM nifedipine combined with different concentrations of vandetanib on the QT interval;

[0032] Figure 8 The effects of 500 nM nifedipine combined with vandetanib on the QT interval of isolated guinea pig hearts; A is a representative graph of the effects of 500 nM nifedipine combined with different concentrations of vandetanib on the QT interval, and B is a quantitative statistical graph of the effects of 500 nM nifedipine combined with different concentrations of vandetanib on the QT interval;

[0033] Fig. 9 The inhibitory effect of 300nM nifedipine and vandetanib on the proliferation of TT cells;

[0034] Fig.10 This is the combined index effect diagram of TT cells treated with 300 nM nifedipine and vandetanib. DETAILED DESCRIPTION

[0035] The following examples are provided for a better understanding of the present invention, but are not intended to limit the best mode of implementation, nor to limit the content and protection scope of the present invention. Any product identical or similar to the present invention obtained by anyone under the inspiration of the present invention or by combining the features of the present invention with other prior arts shall fall within the protection scope of the present invention.

[0036] If no specific experimental steps or conditions are specified in the examples, the conventional experimental steps or conditions described in the literature in the field can be used. If no manufacturer is specified for the reagents or instruments used, they are all conventional reagent products that can be obtained commercially.

[0037] Example 1 Study on the Cardiotoxic Effects of Vandetanib

[0038] 1. Experimental Materials

[0039] 1. Experimental animals and cells: Healthy adult guinea pigs (weight 250-300 g) were purchased from Beijing Sibeifu Experimental Animal Technology Co., Ltd. HEK293 cells stably expressing Kv4.3, Kv11.1, and Kir2.1 channels, and CHO cells stably expressing Nav1.5 channels.

[0040] 2. Experimental reagents: Vandetanib (laboratory internal number SG7018) was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., NaCl, KCl, Na2-Phosphocreatine, Mg-ATP, D-glucose, L-Glutamicacid, NaHCO3, KH2PO4, MgCl2, CaCl2·2H2O were all purchased from Sigma, USA, isoflurane (Rayward Company), and heparin sodium injection (Chengdu Haitong Pharmaceutical Co., Ltd.).

[0041] 3. Experimental instruments: MultiClamp700A amplifier, 1550A digital-to-analog converter, pClamp10.6 acquisition and analysis software (Molecular Devices, USA); puller (P-97, Sutter), MappingLab matrix electrophysiological mapping system (EMS64-USB-1003) (Mappinglab, UK), MappingLab high-resolution fluorescence mapping system (OMSC801) (Mappinglab, UK), Langendorff perfusion system (Sigao Electrophysiology Research Institute), stimulator (VCS-3001) (Mappinglab, UK), ECG recording system (ECG302) (Mappinglab, UK), constant temperature water bath, peristaltic pump.

[0042] 2. Experimental Methods

[0043] (I) Patch clamp experiment

[0044] 1. Vandetanib perfusion method and voltage stimulation protocol

[0045] The experiment uses a patch clamp system for detection. A glass electrode (hard glass electrode made of borosilicate) is pulled with a puller (P-97, Sutter). After filling the electrode with internal liquid, the electrode resistance is between 2-5MΩ. During the experiment, the pre-treated cell crawler is placed in a bath, and an independent single cell is selected to adjust the field of view to a clear view. The microelectrode filled with electrode internal liquid is fixed on the amplifier probe, and the electrode is placed in the liquid using a microelectrode manipulator, slowly approaching the cell. After the electrode contacts the cell, negative pressure is applied to form a GΩ seal between the electrode tip and the cell membrane surface. After compensating the electrode capacitance, negative pressure is applied to break the cell membrane and compensate for the series resistance and cell membrane capacitance. The experiment uses 6KHz filtering for electrophysiological recording.

[0046] The following voltage stimulation schemes were used to record the currents of Nav1.5, Kv4.3, Kv11.1, and Kir2.1 channels. After the currents of each channel reached a stable state, different concentrations of vandetanib external solution were sequentially administered to perfuse and flush the cells. During this process, the changes in the current were closely monitored and recorded until it reached a stable state again. Subsequently, the next concentration of vandetanib external solution was switched and the above operation was repeated. Stimulation scheme:

[0047] Nav1.5 channel: The cell is clamped at -120mV, then depolarized from -120mV to -15mV for 100ms; then, the clamping voltage is adjusted to inactivate the channel current by about 20%, for 100ms; finally, the clamping voltage is adjusted to inactivate the channel current by about 50%, for 100ms. Each sweep lasts 2s, and the interval between sweeps is 5s.

[0048] Kv4.3 channels: The cell was clamped at -80 mV, then depolarized from -80 mV to +40 mV for 500 ms, and then repolarized to -80 mV at a rate of 120 mV / 100 ms. The sweep interval was 10 s.

[0049] hERG channel: The cell was clamped at -80 mV, then depolarized from -80 mV to +40 mV for 3 s, then repolarized to -40 mV for 2 s. Sweeps were 10 s apart.

[0050] Kir2.1 channels: cells were clamped at -80 mV and then repolarized to -120 mV for 1 s; finally, sweeps were performed with an interval of 5 s.

[0051] 2. Statistical analysis

[0052] Origin 2021 and Adobe Illustrator 10 were used for data analysis, drawing and image processing. All data are mean ± standard error The paired t test was used for comparison between groups. P ≤ 0.05 was considered statistically significant. The currents recorded before and after the action of vandetanib were normalized, and all data were expressed as mean ± standard error. The concentration-response curves were fitted nonlinearly using the Logistic regression equation, and IC50 was expressed as the half effective inhibitory concentration.

[0053] (II) High-resolution fluorescence mapping experiment

[0054] 1. Removal of guinea pig heart and establishment of Langendorff perfusion model

[0055] Guinea pigs were weighed and anticoagulated with sodium heparin (3125U / kg) intraperitoneally. After 15 minutes, 0.5ml of isoflurane was used for volatilization anesthesia in a closed space. After successful anesthesia, the animals were killed by cervical dislocation, the heart was exposed, the heart and surrounding related tissues were quickly cut off, and placed in a pre-cooled KH solution in a culture dish. The excess tissue around the aorta was cut off, and the freed aorta was clamped with forceps with both hands. The aorta was connected to the perfusion needle, and the aorta and the perfusion needle outlet were ligated with No. 4 thread. The heart was perfused with a syringe to restore the heart to beat and pump out the residual blood. The channel valve was closed and the transfer was carried out. The perfusion system was opened in advance, and the perfusion needle was quickly connected to the perfusion device. The heart was continuously retrogradely perfused with KH solution, and the heart was waited for to restore a stable heart rate and rhythm (the heart rate should be maintained at more than 280 beats / min, the rhythm should be regular without premature beats, and the electrocardiogram waveform should be normal).

[0056] 2. Fluorescence mapping experimental method and data recording

[0057] Electrocardiogram (ECG) electrodes were placed on both sides of the heart to record ECG continuously; Blebbistatin (6 mg / L) was added to 100 ml of circulating KH solution to stop the heart; Pluronic F127 (500 ug / L) was added (Rhod-2 AM was deesterified before recording to assist calcium loading) and circulated for 10 min; the calcium indicator Rhod-2 AM (1 mg / L) was slowly injected into the perfusion tank and circulated for 15 min; the voltage-sensitive dye RH237 (1 mg / L) was slowly injected into the perfusion tank, and the dye-loaded heart was moved to the imaging perfusion chamber; the excitation light was emitted by two 530±25 nm LED light sources and bandpass filtered at 511-551 nm (LEDC-2001, UK MappingLab); the emitted light from the heart was collected by an objective lens, and the signal was separated at 630 nm using a dichroic mirror. The membrane potential (Vm) signal was long-pass filtered at 700 nm, while the intracellular Ca 2+ The signal was filtered with a 590nm bandpass filter (bandwidth 35nm). Two CMOS cameras (OMS-PCIE-2002, MappingLab, UK) were used to collect the fluorescence signal emitted by the heart at a sampling rate of 0.9kHz. After the isolated heart was stabilized in the perfusion chamber, 0.4μM, 0.8μM, 1.7μM, and 3.4μM vandetanib were administered in sequence from low to high concentrations. The concentration of vandetanib mother solution was 10mM. The administration volume of each concentration was calculated according to the mother solution concentration and the volume of the solution in the circulation tank. Each concentration acted for 15min. After the drug effect was stable, the next concentration was administered until the set highest concentration. After the recording was completed, the changes in intracellular calcium signals, action potentials, and excitation conduction at different times were analyzed.

[0058] 3. Experimental Results

[0059] like Figure 1-4 As shown in the figure, the patch clamp experiment results showed that vandetanib had an inhibitory effect on the main ion channels involved in the composition of cardiac action potential, but the degree of inhibition was different. The IC50 of hERG current was 0.53μM, the IC50 of Nav1.5 channel was 17.1μM, the IC50 of Kv4.3 channel was 17.48μM, and the IC50 of KCNQ1 / E1 channel was 33.55μM. Among them, the inhibitory effect on hERG current was the strongest, and the cursor measurement experiment showed that compared with the control group, the QT interval of the guinea pig heart in the vandetanib group was prolonged in a concentration-dependent manner ( Figure 4 ).

[0060] 4. Experimental Conclusion

[0061] Vandetanib mainly inhibits hERG current and prolongs the QT interval in a concentration-dependent manner.

[0062] Example 2 Effect of Vandetanib Combined with Nifedipine on the QT Interval of Isolated Guinea Pig Hearts

[0063] 1. Experimental Materials

[0064] 1. Experimental animals: Healthy adult guinea pigs (weight 250-300 g) were purchased from Beijing Sibeifu Experimental Animal Technology Co., Ltd.

[0065] 2. Experimental reagents: Vandetanib (Shanghai Aladdin Biochemical Technology Co., Ltd.), nifedipine (Shanghai Aladdin Biochemical Technology Co., Ltd.), NaCl, KCl, Na2-Phosphocreatine, Mg-ATP, D-glucose, L-Glutamic acid, NaHCO3, KH2PO4, MgCl2, CaCl2·2H2O were all purchased from Sigma, USA, isoflurane (Rayward Company), and heparin sodium injection (Chengdu Haitong Pharmaceutical Co., Ltd.).

[0066] 3. Experimental instruments: MappingLab matrix electrophysiological mapping system (EMS64-USB-1003) (Mappinglab, UK), Langendorff perfusion system (Sko Institute of Electrophysiology), stimulator (VCS-3001) (Mappinglab, UK), ECG recording system (ECG302) (Mappinglab, UK), constant temperature water bath, peristaltic pump.

[0067] 2. Experimental Methods

[0068] 1. Removal of guinea pig heart and establishment of Langendorff perfusion model

[0069] The guinea pigs were weighed and anticoagulated with sodium heparin (3125U / kg) intraperitoneally. After 15 minutes, 0.5ml of isoflurane was used for volatilization anesthesia in a closed space. After successful anesthesia, the animals were killed by dislocation of the neck, the heart was exposed, the heart and surrounding related tissues were quickly cut off, and placed in a pre-cooled KH solution in a culture dish. The excess tissue around the aorta was cut off, and the freed aorta was clamped with forceps with both hands. The aorta was connected to the perfusion needle, and the aorta and the perfusion needle outlet were ligated with No. 4 thread. The heart was perfused with a syringe to restore the heart to beat and pump out the residual blood. The channel valve was closed and the transfer was carried out. The perfusion system was opened in advance, and the perfusion needle was quickly connected to the perfusion device. The heart was continuously perfused with KH solution in a retrograde manner, and the heart was waited for to restore a stable heart rate and rhythm (the heart rate should be maintained above 270 beats / min, the rhythm should be regular without premature beats, and the electrocardiogram waveform should be normal).

[0070] 2. Drug administration method and experimental record

[0071] After 15 minutes of stable perfusion of the heart, the circulating KH solution was started. The circulating KH solution volume in the container and the pipeline was 70 ml. ECG electrodes were immediately attached to the sinoatrial node and the apex of the heart. The stimulation electrode was attached to the apex of the heart. The matrix multi-channel electrophysiological mapping electrode pen (PA06408080303) with 1-64 channels (recording channels of the pen-type electrodes of the electrophysiological mapping system, which is part of the experimental equipment) was attached to the left ventricle, and the matrix multi-channel electrophysiological mapping electrode pen (PA06408080303) with 65-128 channels was attached to the right ventricle (schematic diagram as shown in Figure 3 ). After stabilization, the effects of the drug on ventricular conduction velocity before and after drug administration under 6 Hz stimulation were observed and recorded according to the following experimental scheme.

[0072] Dosage method: 1. Effects of nifedipine at different concentrations on the QT interval of the heart, tested concentrations: 0.1μM, 0.3μM, 1μM, mother solution concentration: 10mM. Calculate the volume of nifedipine solution required to be added according to 70ml of circulating KH solution, first add low concentration nifedipine into the circulation tank, mix well, circulate for 15min, and add the next concentration of nifedipine in sequence according to the same operation steps after the drug effect is stable, and repeat the circulation and mixing process until the set maximum concentration is reached; 2. Effect of nifedipine and vandetanib combined on cardiac QT interval, nifedipine stock solution: 10mM, vandetanib stock solution: 10mM; calculate the volume of the drug solution to be tested required to be added according to 70ml of circulating KH solution, pre-add 0.1 / 0.3 / 0.5μM nifedipine into the circulation tank, mix well, circulate for 15min, and after the drug effect is stable, add 0.4μM, 0.8μM, 1.7μM, and 3.4μM vandetanib in sequence according to the same dosing operation, and record the experimental results.

[0073] 3. Experimental Results

[0074] Different concentrations of nifedipine can shorten the QT interval of isolated guinea pig hearts in a concentration-dependent manner ( Figure 5 ); Compared with the use of vandetanib alone in Example 1, 0.1, 0.3, and 0.5 μM nifedipine can offset the QT interval prolongation effect caused by 0.4-3.4 μM vandetanib ( Figure 6 , 7 , 8).

[0075] 4. Experimental Conclusion

[0076] The combined use of nifedipine and vandetanib can shorten the excessively prolonged QT interval and reduce the cardiotoxicity of vandetanib.

[0077] Example 3: Inhibitory effect of vandetanib combined with nifedipine on cancer cell proliferation

[0078] 1. Experimental Materials

[0079] 1. Experimental cells: Human medullary thyroid carcinoma TT cells (CL-0457), purchased from Wuhan Pronocell Life Science Technology Co., Ltd.

[0080] 2. Experimental reagents: Vandetanib (Shanghai Aladdin Biochemical Technology Co., Ltd.), Nifedipine (Shanghai Aladdin Biochemical Technology Co., Ltd.), Ham's F-12K (Kaighn's) medium (Gibco), fetal bovine serum (PAN), CCK-8 reagent (serial number: G021-1-2, purchased from Nanjing Jiancheng Bioengineering Institute).

[0081] 3. Experimental instruments: CO2 incubator (BIOBASE), microplate reader (Biotek).

[0082] 2. Experimental Methods

[0083] 1.CCK-8 Experiment

[0084] TT cells were cultured in F-12K cell culture medium containing 1% penicillin-streptomycin solution (double antibody) and 10% fetal bovine serum at 37°C and 5% CO2 incubator. The cells were digested with trypsin and counted using a blood cell counting plate. 100 μL per well was inoculated into a 96-well cell culture plate (cell concentration was 1×10 4 cell / mL), after culturing in a 37°C, 5% CO2 incubator for 24 hours, different concentrations of vandetanib and a certain concentration of nifedipine were added, and then placed in a 37°C, 5% CO2 constant temperature incubator for 72 hours. On the third day, the solution was changed according to the original gradient concentration of the drug, and then cultured for another 72 hours. After that, 10 μL of CCK-8 solution was added to each well, and the cells were placed in a 37°C, 5% CO2 constant temperature incubator for another 1-4 hours to terminate the culture. The absorbance (OD) value of each well at 450 nm was measured using an enzyme marker.

[0085] 2. Data Analysis and Plotting

[0086] IC50: also known as the half effective inhibitory concentration, that is, the drug concentration when the cell survival rate is 50%. Cell survival rate (%) = (experimental group OD-blank group OD) / (control group OD-blank group OD) × 100%. The CCK-8 results were processed using GraphPadPrism9 software to calculate the IC50 value and the combined index (CI).

[0087] 3. Experimental Results

[0088] like Fig. 9As shown, the IC50 of vandetanib for TT cells is 0.34 μM, and the IC50 of vandetanib combined with 0.3 μM nifedipine for TT cells is 0.45 μM. Fig.10 As shown, by calculating the combination index, it can be concluded that the combination of nifedipine and vandetanib does not affect the efficacy.

[0089] 4. Experimental Conclusion

[0090] The combined use of 0.3 μM nifedipine and vandetanib did not affect the IC50 value of vandetanib itself, proving that the combined use of the two drugs did not affect the efficacy of vandetanib.

[0091] In summary, since the drug effect of vandetanib and the extension of the QT interval are concentration-dependent, if the dosage of the drug is reduced to reduce the side effect of cardiac toxicity, the anti-cancer effect of the drug itself will be affected. The drug combination of nifedipine and vandetanib described in the present invention, from the experimental results, can shorten the QT interval when vandetanib is used alone without affecting the anti-cancer effect, thereby reducing the cardiac toxicity problem caused by vandetanib.

[0092] This drug combination can improve the current situation that "patients have to reduce the dosage of vandetanib due to cardiac toxicity, resulting in the drug not reaching the optimal concentration", thereby indirectly increasing the effectiveness of the drugs. It also shows that the combination of vandetanib and nifedipine can play a role in reducing toxicity and increasing efficacy.

[0093] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.

Claims

1. Use of vandetanib and its pharmaceutically acceptable salts in combination with nifedipine and its pharmaceutically acceptable salts in the preparation of drugs for treating cancer and long QT syndrome.

2. A pharmaceutical composition, characterized in that It contains the following two active ingredients: Vandetanib and pharmaceutically acceptable salts thereof; and Nifedipine and pharmaceutically acceptable salts thereof.

3. The pharmaceutical composition according to claim 2, characterized in that The molar ratio of nifedipine and its pharmaceutically acceptable salt to vandetanib and its pharmaceutically acceptable salt is (0.1-0.5):(0.4-3.4).

4. The pharmaceutical composition according to any one of claims 2 to 3, characterized in that The invention also contains pharmaceutically acceptable excipients, which include at least one of excipients, binders, disintegrants, emulsifiers, preservatives, suspending agents, fragrances, pH regulators, flocculants and deflocculating agents, surfactants, fillers, lubricants, thickeners, humectants, plasticizers, antibacterial agents, coating materials, foaming agents, defoaming agents, bacteriostatic agents, isotonic regulators, and stabilizers.

5. The pharmaceutical composition according to any one of claims 2 to 4, characterized in that The pharmaceutical composition is prepared into a pharmaceutical preparation.

6. The pharmaceutical composition according to claim 5, characterized in that The dosage form of the pharmaceutical preparation is selected from tablets, effervescent tablets, atomizers, gels, granules, pills, capsules, dripping pills, suspensions, sustained-release agents, controlled-release agents or injections.

7. The pharmaceutical composition according to claim 6, characterized in that The pharmaceutical preparation is an oral preparation.

8. Use of the pharmaceutical composition according to any one of claims 2 to 7 in the preparation of drugs for treating cancer and long QT syndrome.

9. The use according to claim 1 or 8, characterized in that The cancer includes thyroid cancer, liver cancer, lung cancer or breast cancer.

Citation Information

Cited By

  • Application of tannic acid in preparation of medicine for treating toxic and side effects caused by Vandetanib

    CN119925394A